Please login to the form below

Not currently logged in
Email:
Password:

Vitrakvi

This page shows the latest Vitrakvi news and features for those working in and with pharma, biotech and healthcare.

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

As Vitrakvi and Rozlytrek lead with their TA indications, the challenges faced by these therapies are wholly different to Keytruda. ... Vitrakvi and Rozlytrek target NTRK gene mutations and fusions in patients with locally advanced or metastatic disease

Latest news

More from news
Approximately 4 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... Vitrakvi(larotrectinib) gained FDA approval in late November to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...